JP2023526449A5 - - Google Patents
Info
- Publication number
- JP2023526449A5 JP2023526449A5 JP2022570566A JP2022570566A JP2023526449A5 JP 2023526449 A5 JP2023526449 A5 JP 2023526449A5 JP 2022570566 A JP2022570566 A JP 2022570566A JP 2022570566 A JP2022570566 A JP 2022570566A JP 2023526449 A5 JP2023526449 A5 JP 2023526449A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- sequence
- park2
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063028335P | 2020-05-21 | 2020-05-21 | |
| US63/028,335 | 2020-05-21 | ||
| PCT/US2021/033758 WO2021237158A1 (en) | 2020-05-21 | 2021-05-21 | Gene therapy delivery of parkin mutants having increased activity to treat parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526449A JP2023526449A (ja) | 2023-06-21 |
| JP2023526449A5 true JP2023526449A5 (https=) | 2024-04-23 |
Family
ID=78707645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570566A Pending JP2023526449A (ja) | 2020-05-21 | 2021-05-21 | パーキンソン病を治療するための、増加した活性を有するパーキン変異体の遺伝子治療送達 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12133897B2 (https=) |
| EP (1) | EP4153760A4 (https=) |
| JP (1) | JP2023526449A (https=) |
| AU (1) | AU2021273979A1 (https=) |
| CA (1) | CA3179402A1 (https=) |
| WO (1) | WO2021237158A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020011386A (es) | 2018-04-27 | 2021-01-29 | Spacecraft Seven Llc | Terapia genica para la degeneracion del snc. |
| EP4153760A4 (en) | 2020-05-21 | 2024-08-21 | Nysnobio GT, LLC | GENE THERAPY ADMINISTRATION OF PARKIN MUTANTS WITH ENHANCED ACTIVITY FOR THE TREATMENT OF PARKINSON'S DISEASE |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1131424B1 (fr) * | 1998-11-19 | 2009-08-19 | Aventis Pharma S.A. | Mutations du gene de la parkine, compositions, methodes et utilisations |
| US7998667B1 (en) * | 1998-11-19 | 2011-08-16 | Aventis Pharma S.A. | Mutations of the parkin gene, compositions, methods and uses |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| WO2009026116A2 (en) * | 2007-08-16 | 2009-02-26 | Genizon Biosciences, Inc. | Genemap of the human genes associated with longevity |
| EP2524037B1 (en) * | 2010-01-12 | 2018-05-16 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| US8603994B2 (en) * | 2010-11-11 | 2013-12-10 | Valted, Llc | Transcriptional repression leading to Parkinson's disease |
| US9464311B2 (en) | 2013-05-02 | 2016-10-11 | E3X Bio, Inc. | Method for identifying modulators of ubiquitin ligases |
| WO2017191274A2 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| MX2020011386A (es) * | 2018-04-27 | 2021-01-29 | Spacecraft Seven Llc | Terapia genica para la degeneracion del snc. |
| US12448629B2 (en) * | 2018-10-05 | 2025-10-21 | University Of Massachusetts | rAAV vectors for the treatment of GM1 and GM2 gangliosidosis |
| EP4153760A4 (en) | 2020-05-21 | 2024-08-21 | Nysnobio GT, LLC | GENE THERAPY ADMINISTRATION OF PARKIN MUTANTS WITH ENHANCED ACTIVITY FOR THE TREATMENT OF PARKINSON'S DISEASE |
-
2021
- 2021-05-21 EP EP21808868.0A patent/EP4153760A4/en active Pending
- 2021-05-21 US US17/327,562 patent/US12133897B2/en active Active
- 2021-05-21 WO PCT/US2021/033758 patent/WO2021237158A1/en not_active Ceased
- 2021-05-21 JP JP2022570566A patent/JP2023526449A/ja active Pending
- 2021-05-21 CA CA3179402A patent/CA3179402A1/en active Pending
- 2021-05-21 AU AU2021273979A patent/AU2021273979A1/en active Pending
-
2024
- 2024-09-30 US US18/901,912 patent/US20250049958A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7588757B2 (en) | Methods of treating Parkinson's disease using recombinant adeno-associated virus virions | |
| JP2023526449A5 (https=) | ||
| Simonato et al. | Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors | |
| MX2010012592A (es) | Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas. | |
| KR20240110849A (ko) | Aadc/gdnf 폴리뉴클레오티드 및 이의 파킨슨병 치료에 있어서의 용도 | |
| IL324039A (en) | Compositions and methods for the treatment of disorders related to cdkl5 deficiency | |
| JP2022536338A5 (https=) | ||
| JP2005507927A5 (https=) | ||
| CN117106825B (zh) | 用于治疗帕金森病的基因治疗载体及其用途 | |
| EP3516052B1 (en) | Recombinant dgkk gene for fragile x syndrome gene therapy | |
| Kim et al. | AAV-GAD gene for rat models of neuropathic pain and Parkinson’s disease | |
| JP7758671B2 (ja) | パーキンソン病を治療するための方法 | |
| Verhaagen et al. | Gene Therapy for Spinal Cord Injury | |
| CN119971081B (zh) | 用于治疗智力障碍的组合物、其应用以及药物筛选方法 | |
| EA051580B1 (ru) | Способы лечения болезни паркинсона | |
| CN115135347A (zh) | 治疗帕金森病的方法 | |
| Sharaf et al. | THE GENETIC CURE FOR BLINDNESS: ADVANCES IN RETINAL THERAPY | |
| CN119351409A (zh) | 优化的编码脑源性神经营养因子的多核苷酸及其应用 | |
| Milkessaa et al. | Current Trends in Treatment of Parkinsons Disease using Gene Therapy | |
| WO2026021447A1 (zh) | 一种M4Di变体以及其治疗疼痛的应用 | |
| RU2021139251A (ru) | Композиции аденоассоциированного вируса для переноса гена arsa и способы их применения | |
| CN121866334A (zh) | 用于调控神经元和星形胶质细胞中的基因表达以评估和/或治疗slc6a1相关的病症的人工表达构建体 | |
| Okada et al. | Shin-ichi Muramatsu, Lijun Wang,*† Kunihiko Ikeguchi, Ken-ichi Fujimoto | |
| CN118725046A (zh) | 具有经修饰的腺相关病毒(aav)衣壳多肽的重组aav | |
| CN116670160A (zh) | Dlx2载体 |